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ABSTRACT
The European autophagy consortium Driving next-generation autophagy researchers towards translation
(DRIVE) held its kick-off meeting in Groningen on the 14th and 15th of June 2018. This Marie Skłodowska-
Curie Early Training Network was approved under the European Union’s Horizon 2020 Research and
Innovation Program and is funded for 4 years. Within DRIVE, 14 European research teams from academia
and industry will train 15 PhD students through applied, cross-disciplinary and collaborative macro-
autophagy/autophagy research. The goal of DRIVE is to stimulate applied approaches in autophagy
research and provide training towards translation, while advancing our knowledge on autophagy in
specific physiological and pathological states. The strong focus on translation will prepare the PhD
students to be at the forefront to exploit autophagy for the development of therapies directly benefit-
ting patients. Thereby, DRIVE will contribute to filling the educational gap that currently exists between
academia and industry, and will prepare its PhD students for alternative and highly flexible professional
paths.
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Autophagy, an emerging field in biomedical life
sciences
Autophagy was first characterized in the 1950s but the study
of its mechanisms and functions remained mostly descriptive
for decades as specific markers to monitor autophagy were
missing [1]. In the beginning of the 1990s, genetic screens in
yeast led to the identification of a number of genes essential
for autophagy, which have been named AuTophaGy-related
(ATG) [1]. The discovery of the ATG genes revolutionized the
field, and detailed follow-up investigations in yeast deciphered
their function and the regulation of autophagy [2]. To date,
over 40 ATG genes primarily involved in autophagy have been
identified; 16 of them compose the core autophagy machinery
required for the formation of autophagosomes in all eukar-
yotes. The specific molecular roles of the ATG genes and how
they act at a mechanistic level, however, remains largely
unknown. Nevertheless, several of these proteins have been
validated as key autophagy markers and their high degree of
conservation incited autophagy research in numerous other
model systems, including mouse and human tissues [3]. This
new investigative wave has led to a series of seminal discov-
eries that revealed numerous physiological and pathological
implications of autophagy [4,5]. These discoveries have fueled
even further autophagy research, making it one of the fastest
emerging fields in biomedical life sciences [1,6].
Autophagy acts at a basal level in most cells and, to main-
tain cellular and organismal homeostasis, can be enhanced in
response to cellular and environmental stresses [7]. Cellular
constituents can be targeted by either nonselective bulk
autophagy or selective types of autophagy, which rely on
receptors that allow specific degradation of the unwanted
cellular components [8]. Selective types of autophagy include
the specific turnover of mitochondria (mitophagy) or the
endoplasmic reticulum (reticulophagy). Such flexibility in
cargo selection allows organisms to use autophagy for a multi-
tude of physiological functions. Autophagy has been impli-
cated in stem cell maintenance, embryonic development, and
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the normal formation and functioning of a wide range of
organs [9]. It also plays a central role in life span extension
(i.e., ageing prevention), metabolism, and multiple aspects of
immunity, including the elimination of intracellular patho-
gens [10]. Defects in autophagy have been implicated in a
wide range of neurodegenerative, cardiovascular, chronic
inflammatory, muscular and autoimmune diseases, and
some malignancies, as well as a recently recognized and
rapidly expanding group of Mendelian neurodevelopmental
multisystem disorders, congenital disorders of autophagy
[11,12]. Not surprisingly in the context of these developments,
autophagy has thus emerged as an attractive therapeutic target
to prevent the onset and/or the progression of various human
illnesses, including specific types of tumors, neurodevelop-
mental, and neurodegenerative disorders (such as Alzheimer
and Parkinson diseases), muscular dystrophies, and specific
infections [4]. Thus, the pharmacological manipulation of
autophagy holds great promise to change the way we cur-
rently treat some of these pathologies [4,13]. Because autop-
hagy can be stimulated by either protein-poor diets (i.e.,
amino acid starvation) [14] or exercise [15], less invasive
combinatorial therapies can also be anticipated.
DRIVE, projecting autophagy research in the future
The manipulation of autophagy has an enormous therapeutic
potential to change the way we treat cancers, neurodevelopmen-
tal and neurodegenerative disorders, and inflammatory and
infectious diseases [4,13]. Despite a rapid increase in our under-
standing of the mechanisms underlying autophagy and its reg-
ulation, translation of this fundamental knowledge into clinical-
grade products with immediate benefit for individual and socie-
tal health is still lagging behind. This translation is currently
hampered by the lack of knowledge about the precise contribu-
tion of autophagy in the different physiological and pathological
conditions, but also the lack ofmodels, biomarkers, and assays to
monitor autophagy in vivo. This gap does not make it possible to
effectively test therapies and drugs before advancing towards a
clinical trial phase. For example, there are currently just 2
autophagy-modulating drugs in phase I or phase II clinical trials
[4], but neither of these (chloroquine/hydroxychloroquine as an
inhibitor and rapamycin as an activator) specifically manipulate
autophagy. Because these compounds are not specific, they also
affect other cellular processes leading to various side effects, such
as immunosuppression in the case of rapamycin. This empha-
sizes the urgent need for models, biomarkers and assays to
develop a new generation of specific autophagy modulators,
and the need to understand autophagy better at a molecular
level.
The Marie Skłodowska-Curie Early Training Network
DRIVE (Figure 1; https://drive-autophagy.eu/) aims at fill-
ing this gap by training 15 PhD students through applied,
cross-disciplinary and collaborative autophagy research.
Through the realization of specific research projects, these
young scientists will become experts in the field of autop-
hagy, with an acute awareness for the possible future
exploitation of autophagy as a therapeutic target. The
DRIVE consortium has enlisted top European autophagy
experts (Figure 2), who have significantly contributed to
our fundamental and clinical understanding of autophagy,
and leverages their complementary competencies to further
stimulate applied autophagy research, through a compre-
hensive approach ranging from the study of the basic
underlying mechanisms to its physiological and pathologi-
cal relevance.
DRIVE’s goals are directed towards conceptual advances,
but also towards the validation of known and new biomar-
kers, and the adaptation of established assays but also the
development of novel ones. For this reason, DRIVE includes
5 industry partners among its members.
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Figure 1. DRIVE logo.
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The PhD training program of DRIVE
With the help of its autophagy experts, its industrial and other
associated partners (see below) (Figures 2 and 3), the goal of
DRIVE is to train, over a period of 4 years, a new generation
of researchers with the necessary knowledge, skills and net-
works to facilitate the future translation of autophagy.
Although the principal educational aim is to train through
research in the laboratory of one of the DRIVE participants, a
complementary educational program has been designed to
optimally achieve the goals of DRIVE. The PhD students
will have at least 2 collaborative research visits at one of the
academic, industrial and/or associated partners. These visits
will expose the PhD students to different professional settings,
but will also allow them to carry out part of their project at a
laboratory with relevant complementary expertise. Moreover,
DRIVE partners and the PhD students will congregate at the
annual DRIVE meetings, where the PhD students will have
the opportunity to present and discuss the advances of their
projects, and receive dedicated feedback from other specia-
lists. Finally, a series of training courses, arranged at these
annual meetings, will equip the PhD students with attributes
that are important for scientists interested in translational
autophagy research. In addition to knowledge obtained
through lectures on key aspects of autophagy, PhD students
will thus acquire additional competencies to exploit their
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Figure 2. DRIVE partners and their institutions or companies, and their distribution around Europe.
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results for the development of products and techniques of
commercial value, including business and entrepreneurship,
patenting, clinical trials, drug discovery, and diagnostic and
pharmaceutical commercialization. They will also learn to
disseminate results and knowledge through modern channels
of communication (topical movies, social media communica-
tion, specific reviews and other outreach activities), to net-
work (exchanges with national and international autophagy
societies and networks, and patient associations), and to
obtain insights into clinical research. As a result, DRIVE
PhD students will be very-well prepared for a variety of
professional career paths and will be ideal catalysts for part-
nerships between the public and private sectors.
The DRIVE’s associated partners
DRIVE has a series of strategic associated partners that will be
pivotal to reach its training goals (Figure 3). Six international
pharmaceutical and biotech companies, ANKAR Pharma
(http://www.ankarpharma.com/), ENYO Pharma (http://www.
enyopharma.com/), Pfizer (https://www.pfizer.com/), QPS
Netherlands (http://www.qps.com/), Sprint Bioscience (http://
www.sprintbioscience.com/en/) and Takeda Oncology (http://
takedaoncology.com/), will host the PhD students for intern-
ships in the private sector and provide lectures on their research
on autophagy. The journalAutophagy (https://www.tandfonline.
com/toc/kaup20/current), Elsevier (https://www.eu.elsevier
health.com/) and e.mersion (http://davidbolinsky.com) will pro-
vide insights into the media and publishing industry through
specific lectures and offers of practical educational tasks. Public
and scientific outreach will be achieved via cooperation with the
European Transautophagy COST action (http://cost-transauto
phagy.eu/) and national autophagy networks, including the Club
Francophone de l’Autophagie (CFATG, http://cfatg.org/en), the
German Autophagy Association (http://autophagie-gbm.de/),
the Nordic Autophagy Society (NAS, https://nordicautophagy.
org/) and the Sociedad Española de Autofagia (SEFAGIA, http://
autofagia.org/). Courses on different aspects of entrepreneurship
will be held by the Healthy Aging Network Northern
Netherlands (https://www.hannn.eu/), Wenckebach Institute of
the University Medical Centre of Groningen (https://www.
umcg.nl/EN/corporate/Departments/wenckebach/about/
Paginas/default.aspx), the University of Groningen Centre of
Entrepreneurship (https://www.rug.nl/society-business/centre-
for-entrepreneurship/), the Stichting Business Generator
Groningen (https://www.businessgeneratorgroningen.nl/) and
the European Platform of Women Scientists (https://epws.org/
). Prof. Dr. Heinz Jungbluth, one of the members of the DRIVE
consortium, and Prof. Dr. Bruria Ben-Zeev, from The Edmond
& Lilly Safra Children’s Hospital at the Sheba Medical Centre
(Ramat Gan, Israel, https://eng.sheba-hospital.org.il/children-
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Figure 3. DRIVE associated partners.
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hospital.aspx) will introduce the PhD students to clinical
research, with a particular focus on autophagy.
Conclusions
DRIVE has principally been designed for the training of 15
young scientists, but it also represents a unique platform to
initiate new and strengthen existing collaborations between
laboratories as well as academic and private partners. The key
events for this type of exchange will be the annual DRIVE
meetings, but the internships of the PhD students will also be
an important vector for the transfer of expertise and techniques,
and for the realization of specific aspects of common projects.
Taken together, DRIVE, like the European Transautophagy
COST action and the NIH-founded Autophagy, Inflammation
and Metabolism (AIM) Center in Albuquerque, New Mexico
[16], is a new international initiative that will further promote
the fundamental, applied and translational research in the
field of autophagy, with the ultimate long-term objective of
providing biomedical solutions to unmet medical needs.
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